Nest Genomics
Lab-agnostic AI platform integrating genomic testing workflows, consent, ordering, and clinical decision support into EHR-based care.
Lab-agnostic AI platform integrating genomic testing workflows, consent, ordering, and clinical decision support into EHR-based care.
Nest Genomics positions its platform as AI-native and lab-agnostic, in contrast to offerings tied to a single sequencing laboratory. Integrated ordering across any lab partner, with configurable test menus by program or specialty, lets health systems adopt the software without changing existing lab relationships.
The company emphasizes coverage of the full patient journey beyond test ordering, combining patient identification, education, consent, results ingestion, and longitudinal clinical decision support inside the EHR. HIPAA compliance, SOC 2 Type II certification, and listings in the Epic Showroom and athenahealth Marketplace support deployment in regulated clinical environments.
Source: nestgenomics.com
Nest Genomics frames its market around the gap between genetic testing guidelines and their uptake in routine care, citing that about one in four people meet national hereditary cancer testing guidelines while fewer than ten percent of those individuals are tested. The thesis is that falling sequencing costs and expanding clinical genetics guidelines push genomic screening into primary care and specialty workflows.
The company sells to health systems, clinics, and specialty practices, and reported use by more than ten health systems and fifty clinics across the United States as of late 2024. Announced growth directions include pediatrics, polygenic risk scores, pharmacogenomics, deeper EMR integrations, and telehealth genetics partnerships.
The record for Nest Genomics is anchored by its founding team's repeat execution in genetic services software, following Clear Genetics, which delivered counseling triage to large patient populations before its 2019 acquisition by Invitae. The company raised an $8.5 million seed round led by B Capital in January 2023 and was part of the Winter 2022 Y Combinator batch.
Post-seed milestones include joining the athenahealth Marketplace in October 2024 and a partnership with Genome Medical announced in January 2025. Published early outcomes from primary care clinics report high completion rates for patient risk assessments and identification of substantial shares of patients meeting genetic testing criteria.
Source:
Source: nestgenomics.com
